មានរបកគំហើញដ៏ធំមួយក្នុងការអភិវឌ្ឍថ្នាំដុំសាច់ខួរក្បាលកុមារភាព។ ដុំសាច់ខួរក្បាលរបស់កុមារគឺជាជំងឺសាហាវទូទៅជាងចំពោះកុមារ។ ការស្រាវជ្រាវថ្មីៗនេះបានរកឃើញថាថ្នាំក្រឡុកថ្មីមួយអាចព្យាបាលដុំសាច់ក្នុងខួរក្បាលកុមារភាពទូទៅ។
Cancer Cell” magazine recently announced that in the UK, about 400 children develop brain ដុំសាច់ each year, of which the prevalence of boys is slightly higher than that of girls.
Are we able to take advantage of the results of tumor gene testing and tailor-made treatments, a strategy often referred to as personalized medicine? This treatment strategy can produce very good results for patients with brain tumors.
Neural myeloblastoma (medulloblastoma) is one of the most common ដុំសាច់សាហាវ of the cerebellum. This ដុំសាច់ខួរក្បាល grows rapidly and most often occurs in children around the age of 5. ជម្រើសព្យាបាល include surgery, radiation, and chemotherapy. Although great progress has been made in treatment methods and techniques, the success rate of treating myeloblastoma still lags far behind other children’s malignancies. In particular, myeloblastoma is a highly aggressive malignancy. Only 40% of patients with medulloblastoma survive, compared with other tumors of a less severe type-with a survival rate of more than 80%.
Researchers in the United States have discovered a new combination therapy for the treatment of highly aggressive neuroblastoma. In laboratory tests, the drug killed ជម្ងឺមហារីក cells without any toxicity to normal cells, and researchers hope to conduct clinical trials of the drug. Robert Wechsler-Reya, an adjunct professor at the Sanford Burnham Prebys Medical Institute, said: “Our goal is to confirm that the drug has low toxicity properties. Because doctors and patients in this case urgently require new clinical treatment options, we will soon apply the drug from the laboratory to clinical treatment.
ដោយការរួមផ្សំជាមួយនឹងថ្នាំដទៃទៀត សមាសធាតុថ្មីដែលរារាំងដុំសាច់ត្រូវបានពិនិត្យនៅក្នុង vitro និង in vivo ។
ការសាកល្បងព្យាបាល for neuroblastoma are often very challenging because of the limited number of patients. In addition, coupled with the variability of the disease, most treatments are only effective for one subtype of patient. Understanding which patients will respond to this treatment is one of the main goals of the trial.
«ប្រសិនបើយើងអាចបង្កើតការព្យាបាលតាមតម្រូវការដោយផ្អែកលើហ្សែននៃដុំសាច់ ដែលជាយុទ្ធសាស្ត្រដែលជាទូទៅគេហៅថាការព្យាបាលបុគ្គល - នេះអាចនាំមកនូវដំណឹងល្អដ៏ធំមួយដល់អ្នកជំងឺដែលមានដុំសាច់ជាក់លាក់។
មាន 40 ប្រភេទផ្សេងគ្នានៃ neuroblastoma ហើយអ្នកជំងឺដែលមានដុំសាច់ក្រុមទីបីមានការព្យាករណ៍អាក្រក់បំផុត - មានតែអ្នកជំងឺ 80% ប៉ុណ្ណោះដែលរស់រានមានជីវិតយូរអង្វែង។ ផ្ទុយទៅវិញការរស់រានមានជីវិតរយៈពេលវែងនៃ neuroblastomas ផ្សេងទៀតគឺមានសុទិដ្ឋិនិយមហើយប្រហែល XNUMX% នៃអ្នកជំងឺអាចរស់បានរយៈពេលវែង។
ភាគច្រើននៃអ្នកជំងឺក្រុមទីបីដែលមាន neuroblastoma មានការបញ្ចេញមតិខ្ពស់នៃ MYC oncogene ដែលជាមូលហេតុនៃការបែងចែកកោសិកាដែលមិនអាចគ្រប់គ្រងបាន និងការបង្កើតដុំសាច់។
There was a study on mice with a third type of neural tube cell tumors that showed histone deacetylase inhibitors (HDACIs) and phosphatidylinositol 3-kinase inhibitors (PI3KIs) might stop mice and people from making neurotubular glioblastomas without doing too much damage to normal cells.
We found several histone deacetylase inhibitors that can kill MYC oncogene-activated neural tube cell tumors without harming normal cell agents (HDACIs),” said Pei Yanxin, an assistant professor at the National Children’s មជ្ឈមណ្ឌលវេជ្ជសាស្ត្រ នៅវ៉ាស៊ីនតោនឌីស៊ី
The most effective of these compounds is panobinostat, which has entered clinical trials in other ប្រភេទនៃជំងឺមហារីក, but has not yet been tested on neuroblastoma.” Dr. Kun-Wei, a postdoctoral researcher at Stanford University, added: “Several other studies have revealed that the mechanism of action of panobinostat is to promote the activation of the FOXO1 gene that can interfere with the oncogenes of MYC.
Phosphatidylinositol 3-kinase inhibitors (PI3KIs) are also thought to have the effect of activating the FOXO1 gene. We hypothesized that panobinostat and phosphatidylinositol 3-kinase inhibitors (PI3KIs) could work together to block កោសិកាមហារីក ការរស់រានមានជីវិត
“It is true that the combined treatment of these two drugs can significantly increase the survival of patients with tumors carrying the MYC gene compared to using a single drug alone.”
